What is Zacks Research’s Estimate for EW Q3 Earnings?

Edwards Lifesciences Co. (NYSE:EW) – Zacks Research increased their Q3 2025 EPS estimates for Edwards Lifesciences in a research note issued to investors on Wednesday, November 20th. Zacks Research analyst R. Department now expects that the medical research company will post earnings of $0.60 per share for the quarter, up from their previous forecast of $0.59. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.57 per share.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, meeting the consensus estimate of $0.67. The business had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The company’s quarterly revenue was up 8.9% on a year-over-year basis. During the same period in the previous year, the business posted $0.59 EPS.

A number of other brokerages also recently commented on EW. Piper Sandler lowered their price objective on Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating for the company in a research note on Friday, October 25th. Evercore ISI lowered their price target on shares of Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating for the company in a research report on Tuesday, October 1st. JPMorgan Chase & Co. lifted their price objective on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the company a “neutral” rating in a research report on Friday, October 25th. Oppenheimer restated an “outperform” rating and issued a $90.00 target price on shares of Edwards Lifesciences in a research report on Thursday, September 12th. Finally, UBS Group cut their price target on Edwards Lifesciences from $90.00 to $75.00 and set a “neutral” rating on the stock in a report on Tuesday, September 10th. Seventeen research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $75.67.

Edwards Lifesciences Stock Up 0.4 %

NYSE:EW opened at $71.56 on Monday. The firm has a market capitalization of $42.20 billion, a PE ratio of 10.33, a price-to-earnings-growth ratio of 3.96 and a beta of 1.12. Edwards Lifesciences has a 52 week low of $58.93 and a 52 week high of $96.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The stock has a 50 day moving average of $67.83 and a 200-day moving average of $75.37.

Insiders Place Their Bets

In other Edwards Lifesciences news, insider Larry L. Wood sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the transaction, the insider now directly owns 198,526 shares in the company, valued at $13,084,848.66. This trade represents a 11.18 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total transaction of $327,850.00. Following the sale, the vice president now owns 46,936 shares in the company, valued at $3,077,593.52. This represents a 9.63 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 40,000 shares of company stock worth $2,657,000. 1.29% of the stock is owned by insiders.

Hedge Funds Weigh In On Edwards Lifesciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Wellington Management Group LLP increased its holdings in shares of Edwards Lifesciences by 86.3% in the 3rd quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company’s stock valued at $2,080,845,000 after purchasing an additional 14,610,123 shares during the period. State Street Corp lifted its position in Edwards Lifesciences by 1.0% in the 3rd quarter. State Street Corp now owns 26,265,633 shares of the medical research company’s stock worth $1,733,270,000 after buying an additional 256,538 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Edwards Lifesciences by 4.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 19,782,909 shares of the medical research company’s stock valued at $1,827,347,000 after buying an additional 809,605 shares during the period. Geode Capital Management LLC grew its holdings in shares of Edwards Lifesciences by 2.2% during the 3rd quarter. Geode Capital Management LLC now owns 13,521,147 shares of the medical research company’s stock valued at $889,050,000 after acquiring an additional 284,918 shares in the last quarter. Finally, Fisher Asset Management LLC increased its stake in shares of Edwards Lifesciences by 9.8% in the third quarter. Fisher Asset Management LLC now owns 9,078,311 shares of the medical research company’s stock worth $599,078,000 after acquiring an additional 806,705 shares during the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.